Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Sanofi to Begin Standalone Generic Operation in Japan
February 24, 2014
-
BUSINESS Plavix Tops Japan Ethical Drug Ranking, Sales Leap 14%: IMS
February 21, 2014
-
BUSINESS MTPC, Daiichi Sankyo Aim to Boost Sales of Struggling Tenelia
February 20, 2014
-
REGULATORY Tokyo Prosecutors Raid Novartis Japan Office over Diovan Ads
February 20, 2014
-
REGULATORY Penalty for Lengthy Drug Price Haggling – Interview 1: “It Can’t Be Helped” Says Idaikyo Exec Koyama
February 19, 2014
-
ACADEMIA Japan Hypertension Society Halts Support for Maker-Linked Seminars, but Gives Leeway for Luncheons
February 18, 2014
-
BUSINESS Blopress AGs Approved, Yet Blurry Prospect for Their June Listing
February 17, 2014
-
REGULATORY 34 Firms Win Approval for Diovan Generics, 31 for Preminent Generics towards June Listing
February 17, 2014
-
BUSINESS Nichi-Iko on Tap to Enter US Market, Remicade Biosimilar Debut Eyed around 2018
February 14, 2014
-
ACADEMIA University of Tokyo Hospital Allegedly Gave Patient Questionnaire Results on SIGN Trial to Novartis without Consent
February 13, 2014
-
REGULATORY Chuikyo Submits Recommendations for FY2014 Revision; Hospitals, Pharmacies with Low Settlement Rates to Face Fee Cuts of Up to 26％
February 12, 2014
-
ORGANIZATION Prof. Tsuchiya Slams Kowa’s Livalo Trademark Suit
February 10, 2014
-
ACADEMIA University of Tokyo Besieged with Medical, Pharma Research Woes, School’s Credibility at Stake
February 7, 2014
-
BUSINESS Kyorin Pushes Easy to Use Inhaler Flutiform, Aims for Higher Market Penetration
February 6, 2014
-
REGULATORY PMDA’s Next 5-Year Plan to Embrace New Generic Unit, Benchmarks for Review Time
February 5, 2014
-
BUSINESS Drug Wholesalers Laud Medical Fee Cuts to Fix Lengthy Haggling, Pharmacy Chains Vexed by Rule
February 4, 2014
-
BUSINESS Teijin Picks Another Pharma Maven for President
February 3, 2014
-
BUSINESS Sanofi Demands Payment of $416 Million from Novartis over Dissolved Equa Deal
January 31, 2014
-
BUSINESS Novartis Suspected of Drafting Letter of Consent for “Sign” Trial
January 30, 2014
-
BUSINESS Shionogi Influenza Campaign Causes Stir among Healthcare Professionals
January 29, 2014
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…